Plasma Metabolomics During Chemotherapy Desensitization: A Pilot Study
Abstract
Background: Rapid drug desensitization permits continued chemotherapy, but no validated blood measurement predicts breakthrough reactions during desensitization.
Objective: To compare paired plasma metabolomic and lipidomic changes during chemotherapy desensitization with those in tolerant controls, and to describe breakthrough and omalizumab encounters.
Methods: In this pilot study, 10 patients undergoing carboplatin or paclitaxel desensitization and four tolerant controls receiving standard infusions contributed 76 draws across 39 encounters (37 with paired pre- and post-infusion draws). Untargeted liquid chromatography-mass spectrometry in four modes yielded 8,646 quality-filtered features (instrument signals). Exact permutation with false discovery rate control compared patient-averaged paired changes from 27 allergic encounters (10 patients) off omalizumab with four control encounters (four patients). Breakthrough and omalizumab comparisons were descriptive.
Results: Allergic patients’ profiles changed from pre- to post-infusion in three of four modes (Holm-adjusted P = .04). Pre-infusion profiles differed between allergic patients and controls in one mode (Holm-adjusted P = .02). Montelukast, a premedication drug, had the smallest P value among annotated pre-infusion differences and was detected in all 33 allergic and no control pre-infusion draws. No feature distinguished allergic from control paired changes at a 5% false discovery rate. Histamine did not consistently increase in seven paired breakthrough encounters (five patients). Hemolysis was more frequent in allergic post-infusion than pre-infusion draws (16 of 35 vs eight of 33).
Conclusion: Profiling during desensitization detected premedication exposure and broad pre-to-post changes largely shared with controls, but no allergy-specific signature. Prospective studies need sampling timed to reactions and medications, comparators matched for premedication and infusion duration, and standardized specimen handling.
Highlights Box: What is already known about this topic?: Desensitization lets most patients with carboplatin or paclitaxel hypersensitivity continue treatment. Breakthrough reactions occur, and no validated blood measurement predicts them.
What does this article add to our knowledge?: In 14 patients, plasma profiling detected premedication signals before infusion and broad pre-to-post changes; no feature distinguished allergic from control changes at a 5% false discovery rate. Histamine did not consistently rise with breakthrough reactions.
How does this study impact current management guidelines?: Biomarker studies during chemotherapy desensitization should match comparators for premedication, time blood draws to symptom onset, and standardize specimen processing; these exploratory findings do not change current desensitization practice.
Related
- Baseline-referenced plasma metabolomic trajectories during early post-exercise recovery: A secondary analysis of public human exercise metabolomics data
- A longitudinal plasma metabolomics dataset of sepsis-associated liver injury across multiple clinical time points.
- Integrative transcriptomics and metabolomics reveal Cry1-associated hepatic alterations and plasma essential fatty acids as biomarkers of residual circadian disruption post-sepsis
- Designing and optimizing an intelligent health informatics management platform for patients undergoing chemotherapy for breast cancer: from needs assessment to pilot testing
- Bedside Bioimpedance and Simple Functional Tests Identify Muscle Function Impairment Predicting Overall Survival in Chemotherapy-treated Metastatic Urothelial Carcinoma: A Retrospective Pilot Study
BibTeX
@misc{asiaee2026plasma,
title = {{Plasma Metabolomics During Chemotherapy Desensitization: A Pilot Study}},
author = {Amir Asiaee and Stacy D. Sherrod and Simona G. Codreanu and Katrina L. Leaptrot and Alexandra C. Schrimpe-Rutledge and John A. McLean and Micah A. McGinnis and Halle C. Petrie and Lauren S. Prescott and Alaina J. Brown and Ronald Alvarez and Elizabeth J. Phillips and Cosby A. Stone},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.30.26366681},
url = {https://www.medrxiv.org/content/10.64898/2026.10.30.26366681v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Plasma Metabolomics During Chemotherapy Desensitization: A Pilot Study
AU - Amir Asiaee
AU - Stacy D. Sherrod
AU - Simona G. Codreanu
AU - Katrina L. Leaptrot
AU - Alexandra C. Schrimpe-Rutledge
AU - John A. McLean
AU - Micah A. McGinnis
AU - Halle C. Petrie
AU - Lauren S. Prescott
AU - Alaina J. Brown
AU - Ronald Alvarez
AU - Elizabeth J. Phillips
AU - Cosby A. Stone
PY - 2026
DA - 2026/10/30
PB - medRxiv
DO - 10.64898/2026.10.30.26366681
UR - https://www.medrxiv.org/content/10.64898/2026.10.30.26366681v1
AB - Background: Rapid drug desensitization permits continued chemotherapy, but no validated blood measurement predicts breakthrough reactions during desensitization. Objective: To compare paired plasma metabolomic and lipidomic changes during chemotherapy desensitization with those in tolerant controls, and to describe breakthrough and omalizumab encounters. Methods: In this pilot study, 10 patients undergoing carboplatin or paclitaxel desensitization and four tolerant controls receiving standard infusions contributed 76 draws across 39 encounters (37 with paired pre- and post-infusion draws). Untargeted liquid chromatography-mass spectrometry in four modes yielded 8,646 quality-filtered features (instrument signals). Exact permutation with false discovery rate control compared patient-averaged paired changes from 27 allergic encounters (10 patients) off omalizumab with four control encounters (four patients). Breakthrough and omalizumab comparisons were descriptive. Results: Allergic patients’ profiles changed from pre- to post-infusion in three of four modes (Holm-adjusted P = .04). Pre-infusion profiles differed between allergic patients and controls in one mode (Holm-adjusted P = .02). Montelukast, a premedication drug, had the smallest P value among annotated pre-infusion differences and was detected in all 33 allergic and no control pre-infusion draws. No feature distinguished allergic from control paired changes at a 5% false discovery rate. Histamine did not consistently increase in seven paired breakthrough encounters (five patients). Hemolysis was more frequent in allergic post-infusion than pre-infusion draws (16 of 35 vs eight of 33). Conclusion: Profiling during desensitization detected premedication exposure and broad pre-to-post changes largely shared with controls, but no allergy-specific signature. Prospective studies need sampling timed to reactions and medications, comparators matched for premedication and infusion duration, and standardized specimen handling. Highlights Box: What is already known about this topic?: Desensitization lets most patients with carboplatin or paclitaxel hypersensitivity continue treatment. Breakthrough reactions occur, and no validated blood measurement predicts them. What does this article add to our knowledge?: In 14 patients, plasma profiling detected premedication signals before infusion and broad pre-to-post changes; no feature distinguished allergic from control changes at a 5% false discovery rate. Histamine did not consistently rise with breakthrough reactions. How does this study impact current management guidelines?: Biomarker studies during chemotherapy desensitization should match comparators for premedication, time blood draws to symptom onset, and standardize specimen processing; these exploratory findings do not change current desensitization practice.
ER -